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BACKGROUND/AIMS—In adults, lower Vitamin D has been associated with increased 
albuminuria. This association has not been extensively studied in youth with or without type 1 
diabetes.
METHODS—We examined the cross-sectional association between vitamin D and albuminuria 
(urine albumin/creatinine ratio [ACR] ≥30 mg/g) in 8,789 participants of the National Health and 
Nutrition Survey 2001–2006 (NHANES), who were 6-19 years old. Further, we examined the 
association between vitamin D and albuminuria in 938 participants from the SEARCH Nutritional 
Ancillary Study (SNAS), a longitudinal cohort of youth with type 1 diabetes.
RESULTS—In NHANES, 5.3%, 19.5%, and 53.7% had vitamin D levels less than 30, 50 and 80 
nmol/L. Albuminuria was present in 12.8% and was more common in younger children, females, 
non-Hispanic whites, non-obese children, and children with hypertension. After adjustments, there 
was no association between vitamin D and albuminuria. In SNAS participants with type 1 
diabetes, we also found no association between baseline vitamin D and subsequent albuminuria, in 
unadjusted or adjusted analyses.
CONCLUSION—We did not find an association between serum vitamin D and albuminuria in 
either non-diabetic youth or those with type 1 diabetes. Further research is needed to more fully 
understand this relationship.
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INTRODUCTION
More than 190,000 people aged <20 years have diagnosed diabetes[1] and this number is 
projected to more than double by 2050.[2] Among individuals with pediatric onset diabetes, 
20–40% develop diabetic kidney disease (DKD) as adults.[3–6] Among people with 
diabetes, those with DKD have the highest risk of mortality.[7, 8] Increased albuminuria is 
the earliest available clinical indicator of DKD, and a strong predictor of DKD progression, 
subsequent cardiovascular events and mortality. In addition, in adults, reduction of 
albuminuria by inhibition of the renin-angiotensin system (RAS) slows DKD progression, 
suggesting that albuminuria is not only an early indicator, but is also a potential therapeutic 
target in DKD.
Several lines of evidence connect low serum 25-hydroxyvitamin D (vitamin D) levels with 
increased risk of albuminuria. Animals deficient in vitamin D receptor develop more severe 
albuminuria and glomerulosclerosis[9] and this defect is reversed by expression of the 
vitamin D receptor in the kidney podocytes.[10] Vitamin D supplementation reduces 
glomerular hypertrophy, podocyte loss, glomerulosclerosis and albuminuria in several 
models of kidney disease, including DKD.[11, 12] Furthermore, in animal models vitamin D 
synergizes with RAS inhibitors to slow DKD progression.[13–15]
In population based studies, lower serum vitamin D levels have been linked to an increase in 
albuminuria in adults with or without diabetes.[16–25] In a large cross-sectional study of 
adults without diabetes, an increase in the prevalence of albuminuria was observed with 
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decreasing vitamin D concentration.[17] In a large prospective cohort study of individuals 
from the general population from Australia, the authors reported a higher incidence of 
albuminuria associated with vitamin D deficiency, and that this deficiency can independently 
predict future albuminuria.[22] However, an association of vitamin D and albumin excretion 
has not been consistently observed in cross-sectional[26] or longitudinal[27] studies. 
Activated vitamin D or its analogs have been shown to reduce albuminuria in adults with 
diabetes in several studies,[28–32] including a randomized placebo-controlled trial.[33] A 
similar association between low vitamin D and albuminuria in children and adolescents has 
not yet been shown, but would form the basis for evaluation of vitamin D supplementation 
as a potential novel therapy for DKD in children. Albuminuria is not uncommon in youth 
with diabetes; in the SEARCH for Diabetes in Youth study (SEARCH), albuminuria was 
present in 9.2% of youth with type 1 diabetes.[34] An advantage of long-term moderate 
vitamin D supplementation is that there are no known adverse effects.
The association between serum vitamin D and albuminuria in children and adolescents with 
diabetes has been examined in two previous studies. Lower vitamin D levels were associated 
with albuminuria in a small cross-sectional study,[35] but this was not replicated in a larger 
cross-sectional study.[36] In the current analysis, we evaluate the association between 
vitamin D and albuminuria in two large studies in children and adolescents with and without 
diabetes, using both cross-sectional and longitudinal analyses.
RESEARCH DESIGN AND METHODS
Study populations
The National Health and Nutrition Examination Survey (NHANES) is a nationally 
representative population-based cross-sectional survey designed to provide estimates of 
health and nutritional status for the non-institutionalized population of the US. NHANES 
2001–2006 was approved by the Institutional Review Board at the Centers for Disease 
Control and Prevention’s (CDC) National Center for Health Statistics. All participants 
underwent standardized in-home interviews, physical examinations and laboratory testing at 
a mobile examination center. This study utilized data obtained in NHANES surveys 
conducted from 2001 to 2006. Serum vitamin D was measured in participants aged ≥ 6 years 
in NHANES 2001–2002 and participants aged ≥ 1 year in NHANES 2003–2006. Urine 
Albumin Creatinine Ratio (ACR) was measured in participants aged ≥6 years in NHANES 
2001–2006. Therefore, this study utilized data from NHANES 2001–2006 participants 6 −19 
years of age who had available serum vitamin D and urine albumin measurements 
(n=8,789). Informed consent was obtained from participants 18 and older. Informed consent 
and parental permission was obtained from participants 12–17 years old and their parents. 
Assent and parental permission was obtained from participants 7–11 years old and parental 
informed consent was obtained from participants <7 years. This study was not considered 
human subjects research by the University of Washington Human Subjects Division because 
of the absence of identifying information and the publically available nature of the data.
The SEARCH Nutrition Ancillary Study (SNAS) is an ancillary study of the SEARCH 
study. The SEARCH study is a multicenter, observational longitudinal study of youth with 
incident diabetes funded by CDC with support from the National Institute of Diabetes and 
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Digestive and Kidney Diseases (NIDDK). Study methods are described in detail in previous 
publications.[37, 38] Briefly, beginning in 2002 and continuing to the present, SEARCH has 
conducted population-based ascertainment of incident diabetes cases in youth aged <20 
years at diagnosis at five locations (Ohio, Colorado, Washington, South Carolina, and 
Southern California). Youth with incident, non-secondary diabetes are invited to participate 
in an in-person visit, during which physical measurements and fasting blood and urine 
samples are obtained. Youth with incident diabetes in the 2002–2005 SEARCH were invited 
to follow-up visits at 1, 2 and 5 years after their initial visit. For SEARCH participants with 
type 1 diabetes, defined by positive autoantibodies to glutamic acid decarboxylase 65 and/or 
insulinoma-associated peptide-2 (IA2) diagnosed in 2002–2005, SNAS collected additional 
nutritional data, including plasma measures of vitamin D obtained from frozen samples, 
which were collected at baseline. For this study, we utilized data from 938 SNAS 
participants with type 1 diabetes, whose diabetes duration was ≥ 3 months at the baseline 
visit, who had completed a baseline visit in 2002–2005 and at least one follow-up visit 
subsequently, and had baseline vitamin D and baseline and follow-up urine albumin and 
creatinine measurements. Of these 938 participants, 66%, 65.1% and 54.4% had a follow up 
visit at 1, 2 and 5 years, respectively. The study was approved by the local institutional 
review board at each site. Written informed consent was obtained from participants aged 18–
19 years. Informed consent and parental assent were obtained from parents or guardians of 
participants <18 years of age and participants themselves, respectively, following particular 
study site Institutional Review Board regulations.
Vitamin D Assessment
Blood samples collected during the NHANES mobile examination center evaluations were 
centrifuged, aliquoted and frozen at −20°C on site. Samples were shipped on dry ice to the 
Division of Laboratory Sciences, National Center for Environmental Health at CDC for 
analysis. Serum 25-hydroxyvitamin D was measured in thawed serum samples using a two-
step extraction and radioimmunoassay using a kit from DiaSorin Inc (Stillwater, MN). Per 
NHANES analytical notes, vitamin D measurements for NHANES 2003–2004 and 2005–
2006, but not NHANES 2001–2002, had to be adjusted for assay drift using a statistical 
adjustment model, based on data from a quality control pool which was collected during this 
interval.[39]
In SNAS, blood samples were obtained after a 10-hour fast and under conditions of 
metabolic stability, defined as no episodes of diabetic ketoacidosis in the preceding month. 
The samples were centrifuged and shipped overnight on cold packs to the SEARCH central 
laboratory (University of Washington Northwest Lipid Research Laboratory, Seattle, WA). 
Upon receipt, samples were aliquoted and stored at −70°C. Vitamin D was measured in 
thawed samples using the DiaSorin chemiluminescence immunoassay (Stillwater, MN, 
USA) at the Nutritional Biochemistry Core of the University of North Carolina Nutrition 
and Obesity Research Center, based on a linkage between specific vitamin D antibody 
coated magnetic particles and an isoluminol derivative. This method uses an antibody as a 
primary binding agent and measures 25(OH)D2 and 25(OH)D3 and has a detectable range 
of 5–320 nmol/l and an intra-assay coefficient of variation of 11.0%.[40] There were 6 
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samples with undetectable levels of vitamin D; these were imputed as 4.9 nmoll/L because 
the lower limit of detection for the assay was 5 nmol/L.
Albuminuria Assessment
In NHANES, spot urine samples collected during the mobile examination center evaluations 
were aliquoted and frozen at −20°C on site. Samples were shipped on dry ice to the central 
laboratory at the University of Minnesota. Urine albumin and creatinine were measured in a 
single spot urine sample. Urine albumin was measured using a solid-phase fluorescent 
immunoassay on a fluorometer, with intra-assay and inter-assay coefficients of variation 
(CV’s) <8%.[41] Urine creatinine was measured using the kinetic Jaffe rate reaction[42] on 
a CX3 analyzer (Beckman ASTRA, Brea, CA).
In SNAS, spot urine samples were obtained in the baseline and follow-up visits, after a 10-
hour fast. Samples were not collected from participants who had a diabetic ketoacidosis in 
the preceding month, were pregnant or menstruating, had a fever or an acute infection or had 
taken an antibiotic in the past week for a urinary tract infection. Samples were processed and 
shipped on cold packs overnight to the SEARCH central laboratory. Urine creatinine was 
measured in single spot urine samples using the Jaffe reaction on the Roche Modular P 
Autoanalyzer with an inter-assay CV of <2%. Urine albumin was measured using an 
immunochemical reaction on a Siemens BNII nephelometer, with an inter-assay CV of 5% 
and 7% for high and low-level quality control samples, respectively.
In both of these studies, only spot urine samples were available. Urine albumin excretion in 
these samples was examined as ACR. Urine ACR was expressed in milligrams of albumin 
per grams of creatinine and was examined both as continuous and binary functional forms. 
When used as a continuous variable, it was log transformed to eliminate the marked right 
skew. As a binary variable, albuminuria was defined as a urine ACR ≥30mg/g.
For all analyses, individuals with nephrotic range proteinuria were excluded because of the 
known association between nephrotic proteinuria and vitamin D deficiency in children and 
adolescents.[43–47]
Covariates
In NHANES, age, sex and race/ethnicity were extracted from participant (or participant’s 
parent or guardian) responses to questionnaires, with race/ethnicity reported as non-Hispanic 
white, non-Hispanic black, Mexican-American, other Hispanic or other.[42] Given smaller 
sample sizes, Mexican-American and other Hispanic were combined for this study. 
Medications taken during the month prior to the NHANES physical examination were 
verified during in-person interviews and pill bottle review. Height and weight were measured 
during the physical examination and body mass index (BMI) was calculated by dividing 
weight (Kg) by height squared (m2). The BMI z-score was calculated using the standardized 
CDC approach.[48] Overweight and obese were defined as a gender-and-age-specific BMI 
of 85th-95th percentile and >95th percentile, respectively, based on year 2000 CDC US 
growth charts. SBP and DBP were ascertained from the average of ≥3 resting measurements 
using a mercury sphygmomanometer by trained staff at the mobile examination center and 
during home examinations. Normal blood pressure was defined as SBP and DBP <90th 
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percentile. Pre-hypertension was defined as SBP or DBP ≥90th but <95th percentile or a 
blood pressure ≥120/80 but <95th percentile. Hypertension was defined as SBP or DBP 
≥95th percentile. Diabetes was defined as self-reported diagnosis of diabetes, Hemoglobin 
A1c (A1c) >6.5% (47.5 mmol/mol) or use of anti-diabetic medications. A1c measurements 
for participants in NHANES 2001–2004 were performed by the Diabetes Diagnostic 
Laboratory at the University of Missouri-Columbia using Primus CLC330 and Primus CLC 
385 (Primus Corporation, Kansas City, MO). Those for NHANES 2005–2006 were 
performed by the Diabetes Laboratory at the University of Minnesota using Tosoh A1c 2.2 
Plus Glycohemoglobin Analyzer (Tosoh Medics, Inc., San Francisco, CA). Both assays used 
a High Performance Liquid Chromatography platform and can be used without a cross-over 
regression, per NHANES analytic notes.[49]
In SNAS, age, sex and race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, 
Asian/Pacific Islander, American Indian, and Multiple/other) were obtained from the 
responses of the participants or participants’ parents or guardians to the SEARCH 
questionnaire. Height and weight were measured to the nearest 0.1 cm and 0.1 kg, 
respectively. Age- and sex-specific BMI z-scores were used for statistical analyses.[50] 
Three blood pressure measurements were obtained using a portable mercury 
sphygmomanometer, and the average of these measurements yielded the Blood Pressure 
(BP) measure assigned. Hypertension was defined as BP>90% for age, sex and height or use 
of antihypertensive medications. Type 1 diabetes diagnosis was confirmed by positivity for 
one or both of the auto-antibodies, glutamic acid decarboxylase-65 (GAD-65) and 
insulinoma-associated-2 (IA-2). These antibodies were measured using a radio-ligand 
binding assays, with cutoff values for positivity of ≥33 and ≥5 NIDDK U/mL for GAD65 
and IA2, respectively. [51] A1c was measured using a dedicated ion-exchange high 
performance liquid chromatography instrument (TOSOH Bioscience).
Statistical analysis
NHANES (cross-sectional) analyses were adjusted for survey design factors including 
cluster sampling (SDMVPSU), stratification (SDMVSTRA), and unequal probability 
weighting adjusted for inclusion of multiple survey waves (WTMEC2YR/3). The 
subpopulation of interest, described above, was specified via domain and was not excluded 
outright from analysis in order to preserve the accuracy of the published survey weights. 
Population estimates of mean vitamin D and prevalence of albuminuria were calculated 
overall and by age, sex, race/ethnicity, BMI category, diabetes status, and hypertensive 
status. The association of albuminuria with vitamin D was examined in logistic regression 
models without covariate adjustment (unadjusted); adjusted for age, sex, race/ethnicity, BMI 
z-score (Model 1); and adjusted additionally for diabetes and hypertension status (Model 2). 
Sensitivity analyses were also conducted by assessing the association of vitamin D with 
continuous ACR, as well as after excluding participants with diabetes. Continuous ACR was 
log-transformed to improve distributional properties.
SNAS (longitudinal) analyses: Baseline vitamin D and prevalence of albuminuria were 
summarized overall and by age, sex, race/ethnicity, BMI category, hypertension status, and 
A1c. The association of baseline vitamin D with subsequent albuminuria was examined 
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using generalized estimating equations with a logit link and compound symmetry covariance 
structure to account for repeated measures per participant. Models included the covariates 
time since baseline (Base Model); additional covariates age, sex, race/ethnicity and BMI 
categories (Model 1); and hypertension status and A1c (Model 2). Participants who met the 
criteria for albuminuria at baseline were excluded from analysis. Sensitivity analyses were 
conducted in the same generalized estimating equations framework to further assess the 
association of vitamin D with (1) continuous ACR, log-transformed to improve 
distributional properties, logit link replaced with identity link; (2) albuminuria in a subset of 
participants with poor glycemic control, defined as A1c>8% (63.9 mmol/mol) at one or 
more time points and; (3) persistent albuminuria, defined as occurrence of albuminuria in 
two or more follow-up visits in participants with no baseline albuminuria.
All analyses applied a significance level of α<0.05 and were performed using SAS (version 
9.12, SAS Institute, Cary, NC).
RESULTS
Cross-sectional analyses using NHANES
Serum vitamin D was right-skewed with 5.3% (95% CI 4.0–6.6%), 19.5% (95% CI 17.6–
21.4%) and 53.7% (95% CI 50.6–56.9%) of individuals having vitamin D levels below 12, 
20 and 32 ng/ml (Figure 1), respectively, corresponding to proposed thresholds of <30, 50 
and 80nmol/L for vitamin D deficiency.[52] Statistically significant lower vitamin D levels 
were associated with older age, female sex, non-white race/ethnicity, obesity, diabetes and 
hypertension. Overall, prevalence of albuminuria was 12.8%. Albuminuria was more 
common in younger children, females, non-Hispanic white, non-obese children and children 
with hypertension (Table 1). Prevalence of albuminuria in children with diabetes (12.1%) 
was similar to those without (12.8%), likely because of the small number of youth with 
diabetes and low overall prevalence of albuminuria in this cohort.
In unadjusted analysis, youth with higher serum vitamin D levels tended to have higher odds 
of albuminuria, though this association did not reach statistical significance (Figure 2 and 
Table 2). After adjustment for demographic (age, sex, race/ethnicity) and anthropometric 
(BMI z-score) variables, there was still no significant association between vitamin D and 
albuminuria (Table 2, Model 1). Further adjustment for blood pressure and diabetes (Table 2, 
Model 2), or exclusion of participants with diabetes (p-value 0.46 in model 2) did not alter 
this finding. Evaluating ACR as a continuous variable also did not affect this finding 
(Supplementary Table 1).
Longitudinal analysis using SNAS
In the SNAS cohort of children and adolescents with type 1 diabetes, serum vitamin D was 
right-skewed with 18.3%, 27.0% and 31.8% of participants having vitamin D levels below 
12, 20 and 32 ng/ml (Figure 3), corresponding to thresholds of <30, 50 and 80nmol/L for 
vitamin D deficiency.[52] Similar to NHANES, lower vitamin D levels were associated with 
older age, non-white race/ethnicity and obesity. Using the gender-blind ACR threshold, 
among 938 SNAS participants studied here, 77 (8.2%), 93 (9.9%) and 170 (18.1%) had 
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albuminuria at the baseline, follow-up or any visit, respectively. Albuminuria prevalence was 
higher in female children and those with poorly controlled diabetes. (Table 3)
We found no significant association between baseline vitamin D and baseline albuminuria 
(p-value 0.62 in model 2). There was also no association between baseline vitamin D and 
subsequent development of albuminuria in unadjusted or adjusted analyses (Table 4). 
Participants with baseline albuminuria were excluded from this analysis; however, a 
sensitivity analysis including them did not alter these conclusions (data not shown). 
Evaluating ACR as a continuous variable did not affect this finding (Supplementary Table 
2). Furthermore, there was no significant association between vitamin D and subsequent 
albuminuria in the subgroup of SNAS participants with poor glycemic control, in follow-up 
visits (p-value 0.13 in model 2). In addition, we found no association between baseline 
vitamin D and subsequent persistent albuminuria (p-value 0.4 in model 2).
DISCUSSION
We found no association between serum vitamin D and albuminuria in children and 
adolescents, either in a cross-sectional analysis of a nationally representative sample 
(NHANES 2001–2006) or in a longitudinal analysis of a cohort of children and adolescents 
with type 1 diabetes (SNAS). This finding was consistently observed, whether the binary or 
continuous form of albuminuria was used. In the cohort with diabetes, this finding was also 
unaffected by the degree of glycemic control.
Lower vitamin D levels have previously been shown to be strongly associated with 
albuminuria in adults.[16–25] While children and adolescents with type 1 diabetes appear to 
have lower circulating vitamin D levels than the general population,[53–55] our findings 
suggest that these lower vitamin D levels are not associated with higher rates of albuminuria.
Examination of albuminuria in children and adolescents is fraught with several difficulties. 
The definition of albuminuria in pediatric cohorts continues to rely on an un-validated 
gender-blind definition, which overestimates albuminuria in girls because of their lower 
daily creatinine excretion.[56–58] To address this problem, we examined vitamin D 
association with the continuous form of ACR and observed similar results to those obtained 
from binary albuminuria. While the continuous ACR may still overestimate the absolute 
albumin excretion in girls, lack of a binary threshold helps avoid misclassification of a 
subset of girls with high normal albumin excretion as albuminuria. However, we found no 
association between vitamin D and the continuous ACR.
Several explanations are possible for why we find no association between circulating 
vitamin D and albuminuria in children. Firstly, albuminuria in children appears to be 
clinically dissimilar from that in adults. Unlike in adults, the vast majority (75–95%) of 
albuminuria in children and adolescents is transient, occurring due to causes such as 
orthostatic proteinuria, which have not been associated with structural kidney disease and 
have benign outcomes in the general population.[59, 60] This may explain the observation 
that not only micro-, but also macroalbuminuria, is highly reversible in children with 
diabetes, even without treatment with RAS inhibitors.[61, 62] If only the pathogenic cases of 
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albuminuria are associated with low circulating vitamin D and the majority of albuminuria 
observed in our study populations is benign, even a large sample size such as those utilized 
here may lack adequate power to detect this association. As an aside, it is worth noting that 
the contribution of orthostatic or transient albuminuria to kidney disease in children with 
diabetes is not known. Secondly, it is possible that even pathogenic albuminuria in children 
is not associated with low circulating vitamin D, suggesting that some of its underlying 
mechanisms may be different from those in adults. Distinguishing these possibilities would 
require examining urine albumin excretion in samples collected in the absence of conditions 
causing transient and orthostatic proteinuria, so that truly pathogenic proteinuria can be 
identified, without misclassification from benign causes. This highlights the difficulty of 
interpreting albuminuria in majority of currently available pediatric cohorts and populations, 
where urine samples are collected under conditions that do not allow this distinction. It also 
emphasizes the importance of accounting for these factors in future pediatric studies. . In 
light of these findings, since 2011 the SEARCH cohort has collected urine samples under 
conditions which would exclude orthostatic and transient albuminuria (e.g. collection of first 
morning void, urine not collected after a fever, strenuous exercise, etc). Future examination 
of samples and data collected under these conditions may shed additional light on 
mechanism and associations of albuminuria in children with diabetes.
This study is subject to several limitations. Firstly, urine albumin excretion was ascertained 
in random, (not timed) urine samples and in samples that were collected under conditions 
which could allow misclassification by transient and orthostatic proteinuria (as discussed 
above). Secondly, serum vitamin D was quantified only at baseline. Additionally, follow-up 
duration in SNAS was short. Finally, analyses of persistent albuminuria excluded 11.5% of 
the SNAS participants who had baseline albuminuria or inadequate follow-up. Like other 
studies of albuminuria in children, this study is limited by a lack of existing age-, sex- and 
race-specific reference values for albuminuria in children and adolescents. We also 
acknowledge limitations of cross-sectional studies for evaluation of association between an 
exposure and a chronically-occurring outcome, such as albuminuria. It is also important to 
note that studying individuals with a longer duration of diabetes than 5 years may have 
yielded different results, as the occurrence of microalbuminuria rises significantly after 10 or 
more years duration.
Despite these limitations, this study is the first to evaluate the association between vitamin D 
and albuminuria cross-sectionally in a large, general population of children within a 
nationally representative study as well as longitudinally in a multicenter cohort of children 
with type 1 diabetes, lending the data wide external generalizability.
Additional strengths are the uniform assessment of albuminuria and vitamin D within each 
study (NHANES and SNAS), meticulous diabetes characterization in SNAS and 
examination of continuous as well as binary measurement of albuminuria. Furthermore, 
though these studies date back to early 2000’s, they were conducted under the same 
standards of care currently in use, which makes these findings relevant to current clinic 
practice.
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In conclusion, we find no evidence of association between circulating 25-hydroxyvitamin D 
and albuminuria in cross-sectional or longitudinal analyses of large, nationally representative 
populations of children and adolescents, with or without type 1 diabetes.
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Figure 1. Distribution of 25-hydroxyvitamin D in NHANES
Participants included children and adolescents 6–19 years of age, participating in NHANES 
2001–2006, who had a serum vitamin D and urine albumin and creatinine measurement 
available. Vitamin D levels of 12, 20 and 32 ng/ml correspond to thresholds of <30, 50 and 
80nmol/L for vitamin D deficiency.
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Figure 2. Unadjusted prevalence of albuminuria by categories of circulating 25-hydroxyvitamin 
D in NHANES
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Figure 3. Distribution of 25-hydroxyvitamin D in SNAS
Study population included SNAS participants with type 1 diabetes, diabetes duration of > 3 
months before the baseline visit with baseline vitamin D and baseline and follow-up urine 
albumin and creatinine measurements. Vitamin D levels of 12, 20 and 32 ng/ml correspond 
to thresholds of <30, 50 and 80nmol/L for vitamin D deficiency.
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Table 2









[0–10) 0.79 (0.49–1.25) 1.20 (0.72–2.01) 1.27 (0.75–2.14)
[10–20) 0.97 (0.69–1.38) 1.34 (0.92–1.94) 1.35 (0.92–1.97)
[20–30) 1.07 (0.78–1.46) 1.22 (0.91–1.65) 1.18 (0.85–1.63)
[30–40) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
[40–50) 1.14 (0.61–2.14) 1.10 (0.60–2.03) 1.01 (0.51–2.02)
≥ 50 1.62 (0.64–4.08) 1.57 (0.64–3.83) 1.80 (0.74–4.35)
p-value 0.37 0.56 0.38
Albuminuria is defined as in Table 1. Effect estimates are expressed as odds ratio, OR (95% Confidence Interval). Model 1 was adjusted for age, 
sex, race/ethnicity, and BMI z-score. Model 2 was additionally adjusted for blood pressure status and diabetes, and thus limited to participants 8–19 
years old for whom systolic and diastolic blood pressures were available. To convert 25-hydroxyvitamin D in ng/ml to nmol/L, multiply by 2.496. 
P-values assess overall association between Vitamin D and albuminuria.
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Table 4









[0–20) 1.12 (0.56 – 2.26) 1.13 (0.56 – 2.28) 1.07 (0.51 – 2.24)
[20–30) 1.26 (0.59 – 2.70) 1.22 (0.57 – 2.62) 1.24 (0.56 – 2.73)
[30–40) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
[40–50) 0.84 (0.25– 2.82) 0.76 (0.22 – 2.59) 0.73 (0.21 – 2.58)
≥ 50 1.57(0.55 – 4.51) 1.39 (0.47 – 4.13) 1.59 (0.51 – 5.02)
p-value 0.87 0.88 0.80
Albuminuria is defined as in Table 1. Effect estimates are expressed as odds ratio (95% confidence interval). The groups with 25-hydroxyvitamin D 
less than 20 were combined due to small sample numbers in each group. Model 1 was adjusted for age, sex, race/ethnicity and BMI z-score. Model 
2 was additionally adjusted for hypertension and hemoglobin A1c. To convert 25-hydroxyvitamin D in ng/ml to nmol/L, multiply by 2.496. P-
values asses overall association between Vitamin D and albuminuria.
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